The Diagnostic Imaging mammography modality focus page provides information, videos, podcasts, and the latest news about industry product developments, trial results, screening guidelines, and protocol guidance that touch on the use of mammography, including 2D digital mammography, digital breast tomosynthesis, and breast ultrasound.
June 27th 2025
While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies
View More
Lung Cancer Tumor Board®: How Do Emerging Data for ICIs, BiTEs, ADCs, and Targeted Strategies Address Unmet Needs in the Therapeutic Continuum for SCLC?
View More
26th Annual International Lung Cancer Congress®
July 25-26, 2025
Register Now!
2025 International Symposium of Gastrointestinal Oncology (ISGIO)
September 12-13, 2025
Register Now!
Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection
View More
(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure
View More
(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment
View More
43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™
November 12-14, 2025
Register Now!
20th Annual New York Lung Cancers Symposium®
November 15, 2025
Register Now!
2nd Annual Hawaii Cancer Conference
January 24-25, 2026
Register Now!
23rd Annual Winter Lung Cancer Conference®
January 23-25, 2026
Register Now!
43rd Annual Miami Breast Cancer Conference®
March 5-8, 2026
Register Now!
19th Annual New York GU Cancers Congress™
March 13-14, 2026
Register Now!
Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies
View More
Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment
View More
Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma
View More
(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice
View More
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
Emerging AI Mammography Model May Enhance Clarity for Initial BI-RADS 3 and 4 Classifications
May 21st 2025In a study involving over 12,000 Asian women, researchers found that an artificial intelligence (AI) model converted over 83 percent of false positives in patients with initial BI-RADS 3 and 4 assessments into benign BI-RADS categories.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Contrast-Enhanced Mammography Study Reveals 24 Percent Lower Sensitivity with Moderate/Marked BPE
April 30th 2025In comparison to minimal or mild background parenchymal enhancement on contrast-enhanced mammography (CEM), researchers found that moderate or marked BPE was associated with a 12 percent lower AUC for breast cancer detection.